[HTML] annalsofoncology.org

[HTML][HTML] Updated safety and clinical activity results from a phase Ib study of atezolizumab+ bevacizumab in hepatocellular carcinoma (HCC)

MJ Pishvaian, MS Lee, BY Ryoo, S Stein… - Annals of …, 2018 - annalsofoncology.org
Background: Agents targeting angiogenesis or PD-L1/PD-1 signalling represent 2 types of
approved treatments (tx) for HCC. In addition to its anti-angiogenic activity, bevacizumab …
被引用次数：96 相关文章

[引用][C] Updated safety and clinical activity results from a phase Ib study of atezolizumab+ bevacizumab in hepatocellular carcinoma (HCC)

MJ Pishvaian, MS Lee, BY Ryoo, S Stein, KH Lee… - Annals of …, 2018 - cir.nii.ac.jp
Updated safety and clinical activity results from a phase Ib study of atezolizumab +
bevacizumab in hepatocellular carcinoma (HCC) | CiNii Research CiNii 国立情報学研究所 …